Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  

| More

Lupin - Q4FY21 Result Update - YES Securities

Posted On: 2021-05-16 06:43:14 (Time Zone: UTC)

Result Highlights

- Revenue declined by 1.6% YoY vs. our estimate of +4% YoY. US sales at US$195mn disappointed due to lower anti-infective sales and lack of flu-led revenues; Domestic business up 8% yoy while ROW markets (-5.6% YoY) and API (-22.2% YoY) saw a decline offset by EMEA (+2.7% YoY) and growth markets (+8% YoY).

- Gross margins expanded by 171 bps YoY to 65.2%, which was further aided by the decline in staff and other expenses (aided by lower R&D - Rs3.4bn vs Rs3.5bn in Q3 FY21), which led to EBITDA expansion of 504bps YoY to 18.7%

- PAT for the quarter stands at Rs4.6bn ( +18.2% YoY vs. our estimate of de-growth of 21% YoY), primarily led by lower ETR and higher other income QoQ

Our view: Lupin guided to double digit growth in US on the low base of FY21 as antibiotic and anti-infective sales were affected along with hardly any flu-related sales. On the other hand, reckon Albuterol sales have been disappointing with guidance of a gradual ramp up in market share likely to keep expectation muted for Q1 FY22. Given the slow ramp up and disappointment in Q4, we factor in 15% growth in FY22 US revenues (on a reduced base) driven by Albuterol ramp up and revival of flu products in H2 FY22. Spiriva would be a key driver of growth next fiscal but we note that it is a top 3 product for innovator; albeit, it can be a FY23 launch but given the experience with Albuterol (and inhalers in general), we expect a gradual ramp up. Domestic sales to rebound on weak base of FY21 and we expect lower R&D to assist margin; factor in improved margin by ~200bps in FY23 - in line with the guidance of 21-22%. We have raised our EPS estimated for FY22/23 by 10%/18%, large part of which is due to lower ETR of 28% in each year; ex-the lowered tax rate assumption, EPS rises by 6% for FY23. Reckon complex injectables can be a more sustained driver beyond FY23, than inhaler portfolio in the next 12 months; accordingly, we still value stock at 20x on FY23 EPS and arrive at TP of Rs1,000. Near term muted expectation for H1 FY22 may result in a better entry point in the stock, in our view. SELL stays.

Shares of LUPIN LTD. was last trading in BSE at Rs.1178.8 as compared to the previous close of Rs. 1210.75. The total number of shares traded during the day was 329802 in over 9148 trades.

The stock hit an intraday high of Rs. 1233 and intraday low of 1165.95. The net turnover during the day was Rs. 392282538.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

CESC Q4FY21 Results Review Report - Loss decline, strong CF make valuation attractive - HDFC Securities

White Goods & Durables - Analysis of pressure cooker market: TTK Prestige is key beneficiary - ICICI Securities

CESC - Good earnings in a challenging environment - ICICI Securities

Somany Ceramics - Walking the talk - ICICI Securities

DB Corp - Rise in newsprint price adds to risk - ICICI Securities

CEAT - Market share ambitions remain strong - ICICI Securities

Consumer Staples & Discretionary - Worm's world view #32: Conversations with paint dealers regarding price hikes - ICICI Securities

Oil & Gas - Oil, gas & spot LNG surge to bring gains for GAIL & OIL - ICICI Securities

Asset Management Companies - Positive trends to support earnings - ICICI Securities

Q4FY21 Result Update - Lemon Tree Hotels - ICICI Direct

Q4FY21 Company Update - Globus Spirits - ICICI Direct

Q4FY21 Result Update - DB Corp - ICICI Direct

Q4FY21 Result Update - Somany Ceramics - ICICI Direct

KEC International: Company Update - Building on diversification - HDFC Securities

LIC Housing Finance - Q4 FY21 Result Update - YES Securities

Entertainment Network Ltd - Beating on solutions business - ICICI Securities

Asahi India Glass - Operating leverage, product mix aid margins - ICICI Securities

Whirlpool of India - Market leading revenue growth - ICICI Securities

Lemon Tree Hotels - Wait for recovery gets longer - ICICI Securities

LIC Housing Finance - Stupendous growth momentum; needs to shore up provisioning and capital buffer - ICICI Securities

Quant Pick - Bank of Baroda - ICICI Direct

Company Update - Amara Raja Batteries - Investor Event Outcome - ICICI Direct

Q4FY21 Result Update - Bhel - ICICI Direct

Q4FY21 Company Update - NRB Bearings - ICICI Direct

CESC - Q4FY21 First Cut - ICICI Direct

Q4FY21 Result Update - Entertainment Network India - ICICI Direct

LIC Housing Finance Results Review Report - Balance sheet beefs up; P&L to stay soft - HDFC Securities

Jubilant FoodWorks 4QFY21 Results Review Report - Missing excitement; recovery priced in - HDFC Securities

BFSI Sector Update - MFI Consultation Paper Takeaways - Incrementally positive for NBFC-MFIs - HDFC Securities

Q4FY21 Result Update - JK Cement - ICICI Direct

Q4FY21 Result Update - Minda Industries - ICICI Direct

Stock Tales - Indo Count Industries - ICICI Direct

IPO Review - Krishna Institute of Medical Sciences Ltd - ICICI Direct

Q4FY21 Company Update - Greenply Industries - ICICI Direct

IPO Review - Dodla Dairy Ltd - ICICI Direct

Lemon Tree Hotels - Q4FY21 First Cut - ICICI Direct

Jubilant Foodworks - Q4FY21 investor call takeaways - YES Securities

Greenply Industries Ltd - Q4 FY21 Result Update - YES Securities

Whirlpool of India Ltd - Q4 FY21 Result Update - YES Securities

New India Assurance Report - CoRs disappoint yet again - HDFC Securities

Maintain BUY on Kajaria Ceramics - Performance shines through; outlook bright - HDFC Securities

Retain ADD on Deccan Cement - Volume strong; high other expense dents margin - HDFC Securities

Reiterate ADD on NHPC - Lower generation impacts earnings - HDFC Securities

Maintain BUY on JK Cement - Robust volume and utilisation - HDFC Securities

Maintain BUY on DLF - Gaining traction - HDFC Securities

Maintain BUY on Capacite Infraprojects - Marginal miss - HDFC Securities

DLF Ltd - Q4 FY21 Result Update - YES Securities

Greenply Industries Ltd - Q4FY21 first cut - YES Securities

Coal India - Coal makes a comeback - ICICI Securities

Kajaria Ceramics - Q4FY21 beat largely priced in - ICICI Securities

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020